NASDAQ$KNSA
Kiniksa Pharmaceuticals Ltd · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Kiniksa meaningfully advanced its business through robust ARCALYST net product revenue and collaboration profit growth.
Kiniksa reported strong Q4 2023 results driven by ARCALYST net product revenue growth. The company anticipates continued growth with ARCALYST in recurrent pericarditis and expects its commercial performance to contribute to a strong financial position.
- ARCALYST Q4 2023 net product revenue was $71.2 million.
- ARCALYST full-year 2023 net product revenue was $233.2 million.
- ARCALYST 2024 net product revenue is expected to be $360 - $380 million, representing ~59% year-over-year growth at the midpoint.
- Cash reserves of $206.4 million are expected to fund operations into at least 2027.
Headline financials
Revenue & EPS history
Kiniksa · Revenue · Quarterly
$83.4M
Revenue by segment
Kiniksa · $64.8M total across 1 segment · Q3 2023
- ARCALYST$64.8M+94.0%100.0%
Forward guidance
Kiniksa expects ARCALYST 2024 net product revenue to be $360 - $380 million, representing ~59% year-over-year growth at the midpoint, and cash reserves of $206.4 million expected to fund operations into at least 2027.
Tailwinds
- ARCALYST 2024 net product revenue expected to be $360 - $380 million, representing ~59% year-over-year growth at the midpoint
- Cash reserves of $206.4 million expected to fund operations into at least 2027
- Significant growth remains with ARCALYST in recurrent pericarditis
- Expect to help an increasing number of patients in the years ahead
- Robust commercial performance to contribute to our strong financial position and ability to drive growth across our business
Headwinds
- Delays or difficulty in enrollment of patients in clinical trials
- Potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials
- Inability to replicate results from earlier clinical trials or studies
- Potential undesirable side effects caused by products and product candidates
- Reliance on third parties as the sole source of supply of the drug substance and drug product used in products and product candidates
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+5.3%
Avg return
Earnings day
+5.2%
Avg return
5 days after
+7.8%
Avg return
30 days after
55%
17 / 31 earnings
Positive
+45.8%
Q3 2021
Best reaction
-16.6%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.5% | +26.7% | +16.6% | |
| Q4 2025 | -4.7% | -6.1% | -1.3% | |
| Q3 2025 | -2.9% | -8.8% | +4.8% | |
| Q1 2025 | +20.5% | +28.8% | +26.6% | |
| Q4 2024 | +0.5% | +3.3% | +19.0% | |
| Q3 2024 | -16.6% | -18.5% | -19.1% | |
| Q2 2024 | +17.8% | +22.1% | +22.5% | |
| Q1 2024 | +4.4% | +4.6% | +12.1% | |
| Q4 2023 | +1.2% | -3.4% | -5.6% | |
| Q3 2023 | -3.4% | +3.3% | +3.1% | |
| Q2 2023 | +35.2% | +26.8% | +18.1% | |
| Q1 2023 | +24.2% | +24.7% | +29.0% | |
| Q4 2022 | -5.6% | -7.8% | -19.7% | |
| Q3 2022 | +8.6% | +21.7% | +49.3% | |
| Q2 2022 | +17.3% | +29.9% | +14.7% | |
| Q1 2022 | +5.1% | -6.8% | -18.4% | |
| Q4 2021 | -6.8% | -3.4% | -7.2% | |
| Q3 2021 | +45.8% | +41.8% | +8.8% | |
| Q2 2021 | -1.4% | -5.4% | -10.0% | |
| Q1 2021 | -9.0% | -11.4% | -19.4% | |
| Q4 2020 | -6.3% | -11.9% | -28.5% | |
| Q3 2020 | -5.9% | -7.2% | +9.6% | |
| Q2 2020 | +0.8% | -1.2% | -14.7% | |
| Q1 2020 | -7.0% | -9.2% | -0.6% | |
| Q4 2019 | -0.7% | +6.1% | -29.5% | |
| Q3 2019 | +15.7% | +24.5% | +80.8% | |
| Q2 2019 | -2.4% | -12.1% | -9.4% | |
| Q1 2019 | +8.2% | +2.6% | +6.5% | |
| Q4 2018 | -6.1% | -0.2% | +20.2% | |
| Q3 2018 | +11.9% | +5.1% | +6.2% | |
| Q2 2018 | +1.7% | +3.5% | +78.2% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro